ES8707295A1 - Procedimiento para la obtencion de anticuerpos monoclonales - Google Patents

Procedimiento para la obtencion de anticuerpos monoclonales

Info

Publication number
ES8707295A1
ES8707295A1 ES542017A ES542017A ES8707295A1 ES 8707295 A1 ES8707295 A1 ES 8707295A1 ES 542017 A ES542017 A ES 542017A ES 542017 A ES542017 A ES 542017A ES 8707295 A1 ES8707295 A1 ES 8707295A1
Authority
ES
Spain
Prior art keywords
monoclonal antibodies
renin
hybridoma cells
derivatives
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES542017A
Other languages
English (en)
Other versions
ES542017A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES8707295A1 publication Critical patent/ES8707295A1/es
Publication of ES542017A0 publication Critical patent/ES542017A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/86—Renin inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

PROCEDIMIENTO PARA OBTENER ANTICUERPOS MONOCLONALES. COMPRENDE: A) CULTIVAR A LAS CELULAS DE HIBRIDOMA PRODUCTORAS DE ANTICUERPOS MONOCLONALES; B) PRECIPITAR AL SOBRENADANTE DEL CULTIVO CON SULFATO AMONICO; Y C) PURIFICAR EL PRECIPITADO POR CROMATOGRAFIA, PARA OBTENER ANTICUERPOS MONOCLONADOS. LOS ANTICUERPOS MONOCLONALES SE ELIGEN ENTRE ANTICUERPO MONOCLONAL R 3-36-16 Y ANTICUERPO MONOCLONAL MARCADO 125I. SE UTILIZAN CONTRA LA RENINA HUMANA.
ES542017A 1984-04-09 1985-04-08 Procedimiento para la obtencion de anticuerpos monoclonales Expired ES8707295A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH178184 1984-04-09

Publications (2)

Publication Number Publication Date
ES8707295A1 true ES8707295A1 (es) 1987-07-16
ES542017A0 ES542017A0 (es) 1987-07-16

Family

ID=4218460

Family Applications (2)

Application Number Title Priority Date Filing Date
ES542017A Expired ES8707295A1 (es) 1984-04-09 1985-04-08 Procedimiento para la obtencion de anticuerpos monoclonales
ES557016A Expired ES8802254A1 (es) 1984-04-09 1986-08-14 Procedimiento para la obtencion de celulas de hibridona que disocian anticuerpos monoclonales con elevada afinidad a la renina humana.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES557016A Expired ES8802254A1 (es) 1984-04-09 1986-08-14 Procedimiento para la obtencion de celulas de hibridona que disocian anticuerpos monoclonales con elevada afinidad a la renina humana.

Country Status (13)

Country Link
US (1) US4780401A (es)
EP (1) EP0158599B1 (es)
JP (2) JPH0669390B2 (es)
AT (1) ATE57392T1 (es)
AU (1) AU591870B2 (es)
CA (1) CA1277261C (es)
DE (1) DE3580056D1 (es)
DK (1) DK165326C (es)
ES (2) ES8707295A1 (es)
FI (1) FI87933C (es)
IE (1) IE57956B1 (es)
NO (1) NO165556C (es)
ZA (1) ZA852557B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
WO1993023433A1 (en) * 1992-05-14 1993-11-25 L.R.S. Diagnostics, Inc. Methods and novel proteins associated with low renin syndrome
DE606516T1 (de) * 1993-01-13 1995-03-16 Idemitsu Kosan Co Gegen menschlichen Ceruloplasmin monoklonaler Antikörper.
WO1994020857A1 (en) * 1993-03-11 1994-09-15 The Regents Of The University Of California Assay for humoral immunity to macromolecules
US6911528B1 (en) * 1994-12-02 2005-06-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US20030167483A1 (en) * 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
WO2002048715A2 (en) 2000-12-14 2002-06-20 The Brigham And Women's Hospital, Inc. Inflammatory markers for detection and prevention of diabetes mellitus
WO2003094856A2 (en) 2002-05-09 2003-11-20 The Brigham And Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker and therapeutic target
WO2003095623A2 (en) * 2002-05-10 2003-11-20 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
CA2536173A1 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
CA2536967A1 (en) * 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
US7491743B2 (en) 2003-08-29 2009-02-17 President And Fellows Of Harvard College Inhibitors of cellular necrosis
AU2004296829A1 (en) 2003-12-05 2005-06-23 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
AU2005207037A1 (en) * 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
EP2927693A1 (en) 2004-10-06 2015-10-07 The Brigham and Women's Hospital Relevance of achieved levels of markers of systemic inflammation following treatment
CA2574535A1 (en) * 2004-11-15 2006-05-26 Nitromed, Inc. Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use
EP1846380A4 (en) * 2005-01-21 2010-02-17 Nicox Sa HETEROCYCLIC NITROGEN MONOXIDE DONOR COMPOSITIONS CONTAINING CARDIOVASCULAR COMPOUNDS, AND METHODS OF USING THE SAME
EP1848424B1 (en) * 2005-01-31 2017-04-05 Mylan Laboratories, Inc Pharmaceutical composition comprising hydroxylated nebivolol
JP2008530226A (ja) * 2005-02-16 2008-08-07 ニトロメッド インコーポレーティッド 抗微生物化合物の有機酸化窒素供与体塩、組成物、および使用法
CA2597463A1 (en) * 2005-02-28 2006-09-08 Nitromed, Inc. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
AU2006223392A1 (en) * 2005-03-09 2006-09-21 Nicox S.A. Organic nitric oxide enhancing salts of angiotensin II antagonists, compositions and methods of use
EP1982711A1 (en) 2005-05-31 2008-10-22 Mylan Laboratories, Inc Compositions comprsing nebivolol
WO2007016677A2 (en) 2005-08-02 2007-02-08 Nitromed, Inc. Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
CA2624933A1 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. Methods for treating respiratory disorders
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US7838023B2 (en) * 2005-11-16 2010-11-23 Nitromed, Inc. Furoxan compounds, compositions and methods of use
EP1968584A2 (en) * 2005-12-20 2008-09-17 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
EP1971340A2 (en) * 2005-12-22 2008-09-24 Nitromed, Inc. Nitric oxide enhancing pyruvate compounds, compositions and methods of use
WO2007146229A2 (en) 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
US7897360B2 (en) * 2006-12-15 2011-03-01 Kimberly-Clark Worldwide, Inc. Enzyme detection techniques
EP2541254B1 (en) 2007-04-18 2014-11-12 Health Diagnostic Laboratory, Inc. Diabetes-related biomarkers and methods of use thereof
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
EP2531163A1 (en) 2010-02-01 2012-12-12 The Hospital For Sick Children Remote ischemic conditioning for treatment and preventon of restenosis
SG10201908570RA (en) 2010-03-31 2019-11-28 Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
NZ728724A (en) 2012-05-11 2018-03-23 Reset Therapeutics Inc Carbazole-containing sulfonamides as cryptochrome modulators
WO2014022195A1 (en) 2012-08-01 2014-02-06 Tavakoli Zahra Free flowing, frozen compositions comprising a therapeutic agent
JP2016514693A (ja) 2013-03-15 2016-05-23 プレジデント アンド フェローズ オブ ハーバード カレッジ ハイブリッド型ネクロトーシス阻害剤
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
CN110114676B (zh) * 2016-10-21 2022-03-25 富士瑞必欧株式会社 肾素浓度的免疫学测定方法
CN107007849A (zh) * 2017-06-19 2017-08-04 河北省人民医院 一种建立甲减性心功能不全大鼠动物模型的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies

Also Published As

Publication number Publication date
NO165556C (no) 1991-02-27
US4780401A (en) 1988-10-25
FI87933C (fi) 1993-03-10
JPS6485070A (en) 1989-03-30
ATE57392T1 (de) 1990-10-15
IE850876L (en) 1985-10-09
FI87933B (fi) 1992-11-30
FI851334L (fi) 1985-10-10
DK165326C (da) 1993-03-29
CA1277261C (en) 1990-12-04
DK153385D0 (da) 1985-04-03
FI851334A0 (fi) 1985-04-03
JPH0669371B2 (ja) 1994-09-07
NO851384L (no) 1985-10-10
AU4088685A (en) 1985-10-17
ZA852557B (en) 1985-11-27
EP0158599A3 (en) 1987-12-16
EP0158599B1 (de) 1990-10-10
EP0158599A2 (de) 1985-10-16
JPS60231624A (ja) 1985-11-18
JPH0669390B2 (ja) 1994-09-07
IE57956B1 (en) 1993-05-19
DE3580056D1 (de) 1990-11-15
ES557016A0 (es) 1988-04-16
AU591870B2 (en) 1989-12-21
DK165326B (da) 1992-11-09
DK153385A (da) 1985-10-10
ES8802254A1 (es) 1988-04-16
ES542017A0 (es) 1987-07-16
NO165556B (no) 1990-11-19

Similar Documents

Publication Publication Date Title
ES8707295A1 (es) Procedimiento para la obtencion de anticuerpos monoclonales
DE3274951D1 (en) Composite semipermeable membrane, process for its production, and method of its use
IL73883A (en) Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
HUT37813A (en) Process for production of new, phisiologically activ human polipeptid
ES8307263A1 (es) Un procedimiento para la preparacion de fosfonamidas sustituidas.
ES2007341A6 (es) Un procedimiento para producir m-csf
EP0222330A3 (en) N6-substituted-5'-oxidized adenosine analogs
ES8606396A1 (es) Procedimiento para la preparacion de activadores de plasmi- nogeno de tejidos
EP0232061A3 (en) High-strength steel for valve springs process for producing the steel, and valve springs made of the same
PT83255A (en) Process for the preparation of polypeptides and characteristic antibodies of papillomavirus and diagnostic method thereto
HUT40436A (en) Process for production pirrolo-benzimidasoles and medical preparatives containing thereof
IE851295L (en) Monoclonal human mif
EP0102601A3 (en) Monoclonal antibody, a process for its production and the use of this monoclonal antibody
ES8605812A1 (es) Procedimiento para obtener un preparado de factor xiii
ES8704082A1 (es) Procedimiento para preparar un agente terapeutico a base de celulas tumorales humanas y eventualmente, neuraminidasa.
HUT45035A (en) Process for producing thiazolone derivatives
ES8800725A1 (es) Un procedimiento para producir un anticuerpo monoclonal
PT82215A (en) Process for preparing monoclonal antibodies against atrial natriuretic peptides of humans
SE8404334D0 (sv) 16-fluoro-16,17-didehydro-prostanoids and process for their preparation
EP0166458A3 (en) Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells
HUT34051A (en) Process for contuonisly ensimatic transformation of alfa hydroxicarbonacids to suitable, optically active alpha aminocarbonacids
PT80145A (en) Process for preparing spiro-indenes and spiro-1,2-dihydro-naftalenes useful for treatment of diabetic complications
PT80996A (en) Process for preparing 6-fluoro-chroman-4-carboxylic acid derivatives
MD48C2 (ro) Procedeu de purificare a b-interferonei umane
PL248306A2 (en) Process for preparing 21-acetate of 6-aplha-methyl-17-alpha,21-dohydroxy-4-pregnen-3,20-dione

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20000201